Prelude Therapeutics Incorporated
Prelude Therapeutics Incorporated（PRLD）内幕交易
基于 SEC Form 4 的买入/卖出笔数、买卖比与情绪标签；可在本季度与近12个月之间切换；下方为季度图与交易明细。
SEC EDGAR · FMP · PRLD · 截至 2026年6月9日
活动摘要
买入笔数
6
P-Purchase only
卖出笔数
0
近12个月
买卖比
∞
Buy/Sell (by trades)
整体情绪
Prelude Therapeutics Incorporated内部人在过去近12个月净买入股份，可能反映对公司前景的信心。
▸ 数据来源：SEC EDGAR · Form 3 & 4 · 买入仅计P-Purchase · 卖出仅计S-Sale
截至 2026年6月9日
PRLD 季度内部人买卖趋势
PRLD 内幕交易卖出 · PRLD 内幕交易买入 · 季度活动
Mobile shows last 4Q · Desktop shows full 8Q
▸ 数据来源：SEC EDGAR · Form 3 & 4 · 最近8季度
As of Jun 9, 2026
活跃内部人
近12个月交易最活跃 · PRLD CEO内幕交易
显示全部内部人 · 点击卡片过滤下方交易表
▸ 按reportingName聚合 · 近12月交易次数Top5 · 无额外API
近期内幕交易记录
PRLD 高管卖出股份 · PRLD 董事内幕交易 · SEC Form 4申报
横向滑动查看全部列
| 日期 | 内部人 | 类型 | 股数 | 总金额 | 申报 |
|---|---|---|---|---|---|
| Apr 27, 2026 | RA CAPITAL MANAGEMENT, L.P. 10 percent owner | Other | 1,407,000 | $141 | Form 4 |
| Apr 21, 2026 | Bonita David P Director | Purchase | 1,689,189 | $7.50M⚡ | Form 4 |
| Apr 21, 2026 | Bonita David P Director | Purchase | 1,126,126 | $5.00M⚡ | Form 4 |
| Apr 21, 2026 | ORBIMED ADVISORS LLC Director | Purchase | 1,689,189 | $7.50M⚡ | Form 4 |
| Apr 21, 2026 | ORBIMED ADVISORS LLC Director | Purchase | 1,126,126 | $5.00M⚡ | Form 4 |
| Oct 4, 2025 | Huang Jane President, CMO | Option | 9,375 | — | Form 4 |
| Oct 4, 2025 | Huang Jane President, CMO | Other | 3,355 | $5K | Form 4 |
| Jul 4, 2025 | Huang Jane President, CMO | Option | 9,375 | — | Form 4 |
| Jul 4, 2025 | Huang Jane President, CMO | Other | 3,355 | $3K | Form 4 |
| Apr 4, 2025 | Huang Jane President, CMO | Option | 9,375 | — | Form 4 |
| Apr 4, 2025 | Huang Jane President, CMO | Other | 3,355 | $2K | Form 4 |
| Mar 25, 2025 | Combs Andrew Chief Chemistry Officer | Purchase | 100,000 | $69K | Form 4 |
| Mar 25, 2025 | Vaddi Krishna CEO · Director | Purchase | 675,000 | $467K | Form 4 |
| Mar 21, 2025 | Vaddi Krishna CEO · Director | Purchase | 15,000 | $11K | Form 4 |
| Mar 20, 2025 | Vaddi Krishna CEO · Director | Purchase | 5,416 | $4K | Form 4 |
| Mar 17, 2025 | Vaddi Krishna CEO · Director | Purchase | 9,106 | $7K | Form 4 |
| Mar 14, 2025 | Vaddi Krishna CEO · Director | Purchase | 29,999 | $23K | Form 4 |
| Mar 13, 2025 | Vaddi Krishna CEO · Director | Purchase | 50,000 | $36K | Form 4 |
| Mar 12, 2025 | Vaddi Krishna CEO · Director | Purchase | 47,500 | $34K | Form 4 |
| Jan 4, 2025 | Huang Jane President, CMO | Option | 9,375 | — | Form 4 |
| Jan 4, 2025 | Huang Jane President, CMO | Other | 3,859 | $5K | Form 4 |
| Dec 31, 2024 | Vaddi Krishna CEO · Director | Purchase | 5,000 | $6K | Form 4 |
| Dec 30, 2024 | Vaddi Krishna CEO · Director | Purchase | 10,000 | $12K | Form 4 |
| Dec 23, 2024 | Combs Andrew Chief Chemistry Officer | Purchase | 60,000 | $82K | Form 4 |
| Dec 20, 2024 | Combs Andrew Chief Chemistry Officer | Purchase | 3,075 | $4K | Form 4 |
RA CAPITAL MANAGEMENT, L.P.
10 percent owner
日期
Apr 27
股数
1,407,000
均价
$0.00
总金额
$141
⚡ = 金额≥$100万 · Award/Option价格显示— · 仅Form4 · 仅普通股
▸ 数据来源：SEC EDGAR · Form 4 申报 · ⚡ = 金额≥$100万 · Award/Option 价格显示 —
关于 PRLD 内幕交易
PRLD 内幕交易
Prelude Therapeutics Incorporated（PRLD）内幕交易数据来源于公司内部人（包括Huang Jane (President, CMO), Bonita David P (Director), ORBIMED ADVISORS LLC (Director)）提交的SEC Form 4申报文件。过去12个月内，4位内部人向SEC提交了交易申报。PRLD内部人近期主要在买入，这可能反映预设的10b5-1计划执行，而非方向性判断。
如需查看Prelude Therapeutics Incorporated机构持仓比例和内部人持股百分比，请访问持仓（Ownership）标签页 → Ownership tab →
常见问题
PRLD 内幕交易 · 5个问题Prelude Therapeutics Incorporated（PRLD）的内部人包括高管和董事，如Huang Jane (President, CMO), Bonita David P (Director), ORBIMED ADVISORS LLC (Director)等。过去12个月内，4位内部人向SEC提交了Form 4交易申报。内部人须在交易日期后2个工作日内完成申报。
▸ 数据来源：FMP /stable/insider-trading/search · SEC EDGAR Form 3 & 4 · RSU归属不计入情绪 · As of Jun 9, 2026